Autologous Hematopoietic Stem Cell Transplantation as an Intensive Consolidation Therapy for Adult Patients in Remission from Acute Myelogenous Leukemia

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 10, 2009, Pages 1306-1313

  Jung, Andre S ^a   Holman, Peter R ^a   Castro, Januario E ^a   Carrier, Ewa K ^a   Bashey, Asad ^a   Lane, Thomas A ^b   Nelson, Connie L ^a   Pu, Minya ^b   Messer, Karen ^b   Corringham, Sue M ^a   Ball, Edward D ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute myeloid leukemia; AML; Autologous hematopoietic stem cell transplantation

Indexed keywords

ANTHRACYCLINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MELPHALAN; MITOXANTRONE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; HLA MATCHING; HUMAN; LEUKEMIA REMISSION; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL;

ADULT; AGE FACTORS; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 69749107016     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.06.006     Document Type: Article

References (22)

1. U.S. Government Statistics. Surveillance, Epidemiology, and End-Results (SEER) of the National Cancer Institute (2002), National Cancer Institute, Bethesda, MD
2. Tallman M.S., Gilliland D.G., and Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 106 (2005) 1154-1163
3. Applebaum F.R. Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol 24 (1997) 114-123
4. Ball E.D., Wilson J., Phelps V., and Neudorf S. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up. Bone Marrow Transplant 5 (2000) 823-829
5. Linker C.A., Ries C.A., Damon L.E., et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrrow Transplant 6 (2000) 50-57
6. Revised Recommendations of the International Working Group for Diagnosis. Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21 (2003) 4642-4649
7. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92 (1998) 2322-2333
8. Linker C.A., Damon L.E., Ries C.A., et al. Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplant 29 (2002) 297-301
9. Sutherland D.R., Anderson L., Keeney M., Nayar R., and Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 5 (1996) 213-226
10. Seshadri T., and Keating A. Is there a role for autotransplants in AML in first remission?. Biol Blood Marrow Transplant 15 (2009) 17-20
11. Hamadani M., Awan F.T., and Copelan E.A. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Biol Blood Marrow Transplant 14 (2008) 556-567
12. Frassoni F. Randomised studies in acute myeloid leukaemia: the double truth. Bone Marrow Transplant 25 (2000) 471-473
13. Zittoun R.A., Mandelli F., Willemze R., et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332 (1995) 217-223
14. Burnett A.K., Goldstone A.H., Stevens R.M., et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 351 (1998) 700-708
15. Cassileth P.A., Harrington D.P., Appelbaum F.R., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339 (1998) 1649-1656
16. Harousseau J.L., Cahn J.Y., Pignon B., et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblatiques (GOELAM). Blood 90 (1997) 2978-2986
17. Suciu S., Mandelli F., de Witte T., et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 102 (2003) 1232-1240
18. Cornelissen J.J., van Putten W.L., Verndonck L.F., et al. Results of a HOVON/SAKK donor verus no-donor analysis of myeloablative HLA-identical siblin stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 109 (2007) 3658-3666
19. Keating S., Suciu S., de Witte T., et al. The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlated with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia 17 (2003) 60-67
20. Feller N., Schuurhuis G.J., van der Pol M.A., et al. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia 17 (2003) 68-75
21. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 6 (2000) 548-554
22. Andersson B.S., Kashyap A., Gian V., et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8 (2002) 145-154